| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNISA996393584103316 |
|
|
Autore |
Meredith Edward <1648-1689?> |
|
|
Titolo |
A letter to Dr. E.S. concerning his late letter to Mr. G. and the account he gives in it of a conference between Mr. G. and himself [[electronic resource] /] / from one who was present at the conference |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
London, : Printed by Henry Hills ..., 1687 |
|
|
|
|
|
|
|
Descrizione fisica |
|
|
|
|
|
|
Soggetti |
|
Authority - Religious aspects |
Tradition (Theology) |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Discussion of a letter from Edward Stillingfleet to Thomas Godden. |
Signed at end: E.M. |
Attributed to Edward Meredith. Cf. BM. |
"Publish'd with allowance" |
Reproduction of original in Bodleian Library. |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910822427603321 |
|
|
Titolo |
Advances in cancer drug targets . Volume 3 / / Atta-ur-Rahman, editor ; contributors Alain J. P. Alix [and thirty seven others] |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Sharjah, United Arab Emirates : , : Bentham Science Publishers, , 2016 |
|
©2016 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (278 p.) |
|
|
|
|
|
|
Collana |
|
Advances in Cancer Drug Targets, , 2213-9915 ; ; Volume 3 |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Cancer - Chemotherapy |
Drug targeting |
Drug delivery systems |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references at the end of each chapters and index. |
|
|
|
|
|
|
|
|
Nota di contenuto |
|
CONTENTS; PREFACE ; List of Contributors ; Neutrophil Elastase as a Target in Lung Cancer: the State of the Art ; 1. INTRODUCTION: NEUTROPHIL ELASTASE/Α-1ANTITRYPSIN IMBALANCE AS A LINK BETWEEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG CANCER; 2. MULTIFACETED FUNCTIONS OF NEUTROPHIL ELASTASE IN LUNG CANCER; 3. ENDEGNENOUS NEUTROPHIL ELASTASE INHIBITORS; 3.1. Proteinaceous Inhibitors; 3.2. Natural Compounds; 3.2.1. Glycosaminoglycans; 3.2.2. Phenolics; 3.2.3. Triterpenoids ; 3.2.4. Fatty Acids and Peptide Derivatives; 4. DESIGN OF DUAL NEUTROPHIL ELASTASE / MMP INHIBITORS |
DESIGN OF DUAL HNE-MMP INHIBITORSCONCLUDING REMARKS; ADDITIONAL MATERIAL; 1. Molecular Modeling and Molecular Graphics; 2. Ligand and Receptor Preparation; 3. Docking Protocol; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENTS; ABBREVIATIONS; REFERENCES; Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack ; INTRODUCTION; MATERIALS AND METHODS; Cell Culture; SiRNA Sequences; SiRNA Transfection; Flow Cytometry; Complement-mediated Cytotoxicity Assay (CDC); C3-binding Studies; Real-Time RT-PCR; Statistical Analysis |
|
|
|
|
|
|
|
|
|
|
RESULTSDesign of siRNAs Specific for CD46, CD55 and CD59; SiRNA-mediated Downregulation of mCRP Expression; siRNA-mediated Augmentation of Tumor Cell Complement Lysis and Opsonization; Time-course of siRNA-induced mCRP Inhibition; Stable Downregulation of CD59 Using an Hairpin siRNA Expression Vector; DISCUSSION; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENT; ABBREVIATIONS; REFERENCES; Points of Therapeutic Intervention along the Wnt Signaling Pathway in Hepatocellular Carcinoma ; INTRODUCTION; THE WNT SIGNALING PATHWAY; Overview of the Wnt Signaling; The Wnt/β-catenin Pathway |
Aberrant Activation of the Wnt/β-catenin Pathway in HCCTARGETING THE WNT/Β-CATENIN PATHWAY IN HCC; Targeting the Upstream Components; Endogenous Inhibitors of the Ligand/Receptor Complex; Targeting Wnt Ligands and FZD Receptors ; Targeting the Dishevelled Protein; Cellular Trafficking and Targets; Targeting the β-catenin Destruction Complex; Targeting the β-catenin/TCF Transcriptional Complex; Pitfalls in Targeting the Wnt/β-catenin Pathway; CONCLUSIONS AND PERSPECTIVES ; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGMENT; ABBREVIATIONS; REFERENCES |
Collaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer INTRODUCTION; PATHOLOGY OF OVARIAN CANCER; TRANSITION FROM EPITHELIAL TO MESENCHYMAL PHENOTYPE AND THE PROGRESSION OF CANCER ; EVIDENCE OF EMT IN OVARIAN CANCER; STEM CELLS IN NORMAL OVARIES AND OVARIAN CANCER; SPHERE FORMATION AND THE CANCER STEM CELL PHENOTYPE OF THE OVARY; ASSOCIATION OF EMT AND CSCS: A MERGER FOR POTENTIAL CHEMORESISTANCE IN OVARIAN CANCER |
Cisplatin Induced EMT Generates Ovarian Cancer Stem-Like Cells: A Study on the OVCA 433 Cell Line as an Experimental Model |
|
|
|
|
|
| |